ALX Oncology
Presence
ALX Oncology is one of the...
ALX Oncology is a company listed under the stock ticker ALXO (US).
Executives
View the org chart displaying its 22 main executives
Most searched biographies at ALX Oncology
Popular executive movements at ALX Oncology
- Jason Lettmann, who was Director, is promoted to Chief Executive Officer (posted on September 7 2023).
Create your alert
to follow the executive moves at ALX Oncology.
Biotechnology
ALX Oncology has 2,275 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
- Nurix Therapeutics has just announced a $175 Million fundraising (posted on April 13 2024).
Popular contacts in Biotechnology
News
Press releases by ALX Oncology
- ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma – ALX Oncology
- ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia – ALX Oncology
- ALX Oncology Announces Evorpacept Clinical Program Updates – ALX Oncology
- ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference – ALX Oncology
- ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights – ALX Oncology
- ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma – ALX Oncology
- ALX Oncology Announces Upcoming Virtual Investor Conference Participation – ALX Oncology
- ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights – ALX Oncology
- ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma – ALX Oncology
- ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer – ALX Oncology
- View more press releases Close
Social media about ALX Oncology
- ALX Oncology on Wikipedia, Google News & Yahoo Finance
- ALX Oncology on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Jason Lettmann 
Call ALX Oncology at +1 353...
